Tracking and Cumulative Lifetime Exposure to IGF-I in 6459 Healthy Individuals and in Small-for-gestational-age (SGA) Children Treated With GH
Authors' conclusion
Because IGF-I and IGFBP-3 levels track throughout life, a single measurement reliably reflects lifetime exposure. GH therapy increased the lifetime exposure to IGF-I only slightly and it remained below the average lifetime exposure in the reference population.
Study context
- Population
- Healthy participants aged 0–76 years (9963 serum samples) and SGA children treated with GH
- Participants
- 6,459 vs 9
- Exposure
- Healthy individuals vs SGA children treated with GH
- Healthyn = 6,459reference
- SGAn = 9
- Outcome
- Intraindividual tracking of IGF-I and IGFBP-3 (SDS) by intraclass correlation coefficients (ICCs); cumulative lifetime IGF-I exposure (AUC of predicted SDS trajectory, 0 to 76 years)
Main finding
As reported in the abstract
Intraindividual tracking of IGF-I (SDS), ICC
Male
0.50
ICC · 95% CI 0.47–0.53
Female
0.53
ICC · CI 0.50–0.56
Observational data: associations, not effects.
Further findings
| Outcome | Female | Male | P value |
|---|---|---|---|
| Lifetime IGF-I exposure by sex (healthy)Significantly higher in female | mean 12 723 (SD 3691) | 12 563 (SD 3393) | P = 0.02 |
Lifetime IGF-I exposure in SGA children with GH treatment
- Lifetime IGF-I exposure increased with GH
- from 9512 ± 1889 to 11 271 ± 1689
- Lifetime IGF-I trajectory increased with GH
- from −0.89 SD ± 0.57 to −0.35 SD ± 0.49
Original publication
Tracking and Cumulative Lifetime Exposure to IGF-I in 6459 Healthy Individuals and in SGA Children Treated With GH. J Clin Endocrinol Metab. Published 17 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →